Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epratuzumab I-131

Drug Profile

Epratuzumab I-131

Alternative Names: Anti-CD22 monoclonal antibody LL2-I-131; IMMU LL2-I-131; ImmuRAIT-LL2-I -131; LymphoCide I -131; Monoclonal antibody LL2-I-131

Latest Information Update: 17 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Developer Immunomedics; Repligen Corporation
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
  • 08 Aug 2001 US patent issued to Immunomedics covering the engineering of a glycosylation site on anti-CD22 antibodies for the purpose of attaching drugs or isotopes without affecting targeting
  • 24 Feb 2000 A phase I study in non-Hodgkin's lymphoma has been added to the therapeutic trials section
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top